Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Geriatric Medicines Market Size Changed, over the years?

The market size for geriatric medicines has experienced significant expansion in the recent past. It is anticipated to rise from $1227.91 billion in 2024 to $1430.84 billion in 2025, with a compound annual growth rate (CAGR) of 16.5%. Factors contributing to this growth during the historic period include an increased incidence of stroke, higher prevalence of chronic ailments, a surge in cardiovascular diseases, enhanced government backing, and a growing focus on individualized medicine.

How Much Will the Geriatric Medicines Market Be Worth in 2029?

Anticipations suggest a swift enlargement of the geriatric medicines market in the upcoming years. It’s projected to reach a valuation of $2604.86 billion by 2029, with a compound annual growth rate (CAGR) of 16.2%. This growth over the forecast period is primarily due to the escalating number of old-age related health issues, expanding geriatric population, increased investment in healthcare, the growth in the field of geriatric medicine, and a swelling number of hypertension cases. The forecast period is also expected to witness some significant trends such as the adoption of digital pills and health monitoring wearables, creation of strategies and tools for secure handling of multiple medications, progress in stem cell and gene therapy, wider application of telehealth facilities, and improved procedures for early detection and prevention of diseases related to aging.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20817&type=smp

Which is the Largest Company in the Geriatric Medicines Market?

Major companies operating in the geriatric medicines market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Apotex Inc., Intas Pharmaceuticals Limited, Dr. Reddy’s Laboratories, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Endo Pharmaceuticals Inc.

What Are the Main Market Drivers in the Geriatric Medicines Industry?

The rise in health issues linked to aging is set to boost the expansion of the geriatric medicines market. Health problems related to aging typically escalate in regularity or severity as a result of aging itself. Factors such as extended life spans, improvements in healthcare, and an aging population predominantly contribute to the increased commonality of these age-related health conditions. Geriatric medicines offer specialized treatment for older adults, enhancing their health outcomes and overall quality of life. For example, a report released by the Office for Health Improvement and Disparities (OHID), a UK government department, in March 2023, stated that in 2022, 17.6% of people aged 16 and over reported suffering from a long-lasting musculoskeletal (MSK) condition such as arthritis or chronic back or joint problems. This signifies a growth from the 17.0% incidence recorded in 2021. As a result, the escalating incidence of health conditions associated with aging propels the expansion of the geriatric medicines market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20817&type=smp

How Is the Geriatric Medicines Market Segments Structured?

The geriatric medicines market covered in this report is segmented –

1) By Therapeutics: Analgesics, Antihypertensive, Statins, Proton Pump Inhibitors, Anticoagulant, Antipsychotic, Other Therapeutics

2) By Condition: Cardiovascular, Arthritis, Neurological, Cancer, Osteoporosis, Respiratory, Other Conditions

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Analgesics: Non-Opioid Analgesics (Acetaminophen, NSAIDs), Opioid Analgesics (Morphine, Oxycodone), Topical Analgesics (Lidocaine Patches)

2) By Antihypertensive: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Calcium Channel Blockers, Diuretics, Alpha-Blockers

3) By Statins: Atorvastatin, Simvastatin, Rosuvastatin, Pravastatin, Lovastatin

4) By Proton Pump Inhibitors: Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole

5) By Anticoagulant: Warfarin, Direct Oral Anticoagulants (DOACs): Dabigatran, Rivaroxaban, Apixaban, Heparin

6) By Antipsychotic: Atypical Antipsychotics, Typical Antipsychotics

7) By Other Therapeutics: Antidepressants (SSRIs, SNRIs), Antidiabetic Medications (Insulin, Metformin), Anticonvulsants, Anti-Inflammatory Drugs (Corticosteroids), Cognitive Enhancers (Donepezil, Memantine)

What Strategic Trends Are Transforming the Geriatric Medicines Market?

Leading firms in the geriatric medicines market are focusing on the creation of innovative diabetes treatments to meet the growing need for efficient solutions among the aged population. Diabetes therapy includes revolutionary methodologies that either improve diabetes management or provide potential cures that surpass the traditional practices, enhancing efficacy, safety, and the outcomes for patients. In August 2023, Akums Drugs & Pharmaceuticals Ltd., a pharmaceutical contracting company based in India, publicized the onset of a new combination therapy featuring Vildagliptin SR and Metformin SR. This sophisticated composition is specially designed for the management of Type 2 diabetes in the elderly. It provides effective glycemic control, and also reduces major concerns like hypoglycemia and weight gain, which are especially crucial for the older demographic. The combination of both drugs boosts insulin secretion and effectively lowers blood sugar levels, assuring safety and effectiveness. The therapy has gained regulatory endorsement from the Drug Controller General of India (DCGI).

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/geriatric-medicines-global-market-report

Which Global Regions Offer the Highest Growth in the Geriatric Medicines Market?

North America was the largest region in the geriatric medicines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the geriatric medicines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20817

This Report Delivers Insight On:

1. How big is the geriatric medicines market, and how is it changing globally?

2. Who are the major companies in the geriatric medicines market, and how are they performing?

3. What are the key opportunities and risks in the geriatric medicines market right now?

4. Which products or customer segments are growing the most in the geriatric medicines market?

5. What factors are helping or slowing down the growth of the geriatric medicines market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model